Trial Profile

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elotuzumab (Primary) ; Nivolumab (Primary) ; Dexamethasone; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms CheckMate 602
Sponsors Bristol-Myers Squibb

Most Recent Events

01 Oct 2024 Results assessing safety and efficacy of Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma published in the Clinical Lymphoma, Myeloma & Leukemia
30 Nov 2023 This trial has been completed in Spain according to European Clinical Trials Database record.
28 Apr 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com